Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And here is my submission for the contest.
$19 million even
But I sure do hope Mike wins.
My thoughts also motorcity.
https://www.marijuanamoment.net/dietary-supplement-industry-pushes-congress-to-allow-cbd-product-sales/
It’s coming! We should be in a good place when it does.
I have been reading about this nano technology for delivery of CBD. Does anybody know if it’s just hype or if it actually transports more CBD into the cells quicker?
Nice run up the last few days.
You are right. Just touched $2
Please contact your senators
https://hempsupporter.com/resources/Z
I decided I am not going to panic. Don’t like the downturn in the sp but I like the fundamentals and I’m holding for the long turn. Too many stores carrying plus CBD. And more coming. Everybody knows about CBD. And when I ask my patients if they would mind if I use some CBD with them almost nobody has a problem with it anymore. And many of them are already using it.
But I have figured out how to get it into the body faster. I mix it half-and-half with a product called pain a trate. It sucks the whole compound into the skin or the muscle or the joint, wherever I’m applying it quickly and it warms up so they feel it within one or two minutes and it feels nice. And it feels so nice they want to buy it.
I decided I am not going to panic. Don’t like the downturn in the sp but I like the fundamentals and I’m holding for the long turn. Too many stores carrying plus CBD. And more coming. Everybody knows about CBD. And when I ask my patients if they would mind if I use some CBD with them almost nobody has a problem with it anymore. And many of them are already using it.
But I have figured out how to get it into the body faster. I mix it half-and-half with a product called pain a trate. It sucks the whole compound into the skin or the muscle or the joint, wherever I’m applying it quickly and it warms up so they feel it within one or two minutes and it feels nice. And it feels so nice they want to buy it.
Just went into the convenient store across the street from the clinic and sure enough they got CBD right on the counter. It wasn’t plus CBD but it was a pain relief balm.
At these prices I just couldn’t help myself. Got 5000 more shares at $2.22 right at the close.
Good news.
On Tue, Sep 17, 2019 at 9:31 AM U.S. Hemp Roundtable <info@hempsupporter.com> wrote:
This morning, Senate Majority Leader Mitch McConnell – after consulting closely with the US Hemp Roundtable -- has introduced legislation that would require the FDA to issue formal “enforcement discretion” on the sale of hemp CBD products.
This is a Big Frickin’ Deal. And we need your help to get this passed.
As discussed more fully last week, a primary policy challenge facing the hemp CBD industry has been FDA’s guidance that it is illegal for CBD to be introduced into interstate commerce as a food additive or dietary supplement. While the FDA has announced that it will unveil its timetable to take action toward full legalization this fall, it could be many months before they issue a formal regulation.
Today, the US Senate Appropriations Subcommittee on Agriculture will “mark up” language submitted by Senator McConnell that would require the FDA to formally stand down on any enforcement of its troublesome anti-CBD guidance. Specifically, the language (linked here) would require FDA to:
Within 90 days, provide Congress a report outlining its efforts to develop an enforcement discretion policy on hemp CBD;
Within 120 days, issue its formal enforcement discretion policy on hemp CBD;
Keep the enforcement discretion policy in effect until the agency has implemented its final regulatory process; and
Ensure that going forward, CBD manufacturers would be able share safety data through existing FDA notification procedures to be fully compliant with federal law and policy.
In the short run, the McConnell language would help lift the current regulatory cloud that’s been discouraging financial institutions to work with CBD companies, and that’s encouraged some local government officials to suggest that CBD is illegal in their state. In the long run, it would set forward a fair and expeditious path for hemp CBD products to be formally recognized as safe and legal as a matter of federal law.
The bill will be marked up by the full Senate Appropriations Committee on Thursday, and could go to the full Senate soon.
That’s why we need you TODAY to email your US Senators to encourage them to support McConnell’s language requiring FDA to stand down on hemp CBD.
Please use our online portal to email your Senator today to support the McConnell plan. And while you are there, please encourage your Representative to sign onto the Pingree/Comer letter to the FDA discussed here last week.
CONTACT YOUR MEMBERS OF CONGRESS
News Article
Rise In Mergers And Acquisitions Within Cannabis Industry Continues While Fueling Positive Retail Sales
3:22pm ET 9/5/2019 Globe Newswire
Mentioned in article
ALEAFCVSIHEXOMDCL
According to the Marijuana Business Factbook, an exclusive report by Marijuana Business Daily (MJD) containing market projections, retail sales of medical and recreational cannabis in the United States are on pace to eclipse $12 billion by the end of 2019 - an increase of roughly 35% over 2018 - and could rise as high as $30 billion by 2023. MJD said: "Continued sales gains in recreational markets as well as the rapid development of medical marijuana programs in newly legalized states will spur much of that growth over the coming year. On the recreational side, estimated sales in 2018 were revised up slightly from our original forecast at the beginning of 2018... But by the end of 2018, the number of licensed retail stores and delivery services in California was up considerably, pushing estimated sales past the $2 billion mark." Active cannabis companies in the markets this week include: Medicine Man Technologies, Inc. (OTCQX: MDCL), HEXO Corp (NYSE: HEXO), Aleafia Health Inc. (OTCQX: ALEAF), CV Sciences, Inc. (OTCQB: CVSI).
The report continued: "Sales in mature markets such as Colorado, Oregon and Washington state continue to grow... (and) by the end of 2019, each of those states could post single-digit, year-over-year sales gains - the first time that's happened in a recreational marijuana market. Nationwide, however, rec sales are set for major growth in the coming years, as California and Massachusetts are expected to hit their strides by 2020 and markets such as Maine and Michigan come online."
Medicine Man Technologies, Inc. (OTCQX: MDCL): Medicine Man Technologies announced this week that it has entered into a binding term sheet to acquire Colorado Harvest Company ("Colorado Harvest"), an operator of two leading cannabis dispensaries in Denver and one in nearby Aurora.
Under the terms of the transaction, Medicine Man Technologies will purchase Colorado Harvest for $12.5 million, or 1.25 times its anticipated 2019 revenue of $10 million. The purchase price will consist of $4 million in cash and $8.5 million in Company stock, equating to 2,881,356 shares issued at $2.95 per share. The terms of the transaction can also be referenced in the Company's 8-K, which outlines the closing conditions and are conditioned upon the satisfaction or mutual waiver of certain conditions, including regulatory approval.
"Tim and Ralph are early industry pioneers that built an avid following for their proprietary naturally grown strains when recreational cannabis was legalized in Colorado," said Andy Williams, Co-Founder and Chief Executive Officer of Medicine Man Technologies. "Given their many years of underlying cultivation experience, Tim and Ralph have perfected their formula for growing cannabis naturally with a focus on utmost quality using environmentally sensitive grow practices that many consumers enjoy. Their combined cannabis knowledge even led them to begin producing CO2-extracted cannabis oil that they later turned into a company called O.penVAPE, now the leading cannabis personal vaporizer in the country. Adding their deep retail, cultivation, and product development experience to the Company will prove very beneficial as we continue with our plans to vertically integrate our business and look for future cross-selling opportunities from our expanding operations."
Medicine Man Technologies Also Unveiled its Largest Deal Yet with Entry into a Term Sheet to Acquire a Group of Dispensaries Operating under the Starbuds Brand - Highlights include:
- The Company's addition of a group of five dispensaries will increase the retail footprint and regional coverage of the Company in Colorado
- As part of the agreement, one of the original industry pioneers, Brian Ruden, will join the Company's Board of Directors, enhancing the depth of the senior management team, which is unrivaled in the cannabis industry
- The Company continues to create shareholder value by consolidating some of the most successful cannabis cultivation, manufacturing, and retail operations in Colorado
Read this and additional current news for MDCL at: https://www.financialnewsmedia.com/news-mdcl/
Other recent developments in the biotech industry include:
HEXO Corp (NYSE: HEXO) recently announced that its dried flower cannabis products are now available to Ontario consumers, after finalizing terms with the Ontario Cannabis Store (OCS). HEXO now adds nine of its dried flower offerings in both 3.5g and 15g SKUs to the OCS, including the Company's award-winning Helios dried flower, which was named Best Sativa at the O'Cannabiz 2019 Industry Awards.
Aleafia Health Inc. (OTCQX: ALEAF)'s wholly owned subsidiary, Aleafia Farms Inc., has acquired the farmland directly adjacent to its Port Perry Outdoor Grow facility. The purchase will allow the Company to commence its Outdoor Grow Phase II expansion, adding an additional 60 acres of cannabis cultivation area, for a total of 86 acres. The transaction closed on September 3, 2019, with a cash purchase price of $1.2 million. Following closing, the Company will commence the process of having the new property's address amalgamated with the current Port Perry address. This would allow Aleafia Farms to request an amendment to its existing Health Canada licence, rather than applying for an entirely new Cultivation Licence.
CV Sciences, Inc. (OTCQB: CVSI), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, recently announced further expansion of its industry-dominating PlusCBD(TM) Oil brand into the specialty retail channel with The Vitamin Shoppe, Inc. (VSI).
CV Sciences' expansion broadens distribution and availability of a broad assortment of the Company's best-selling PlusCBD(TM) Oil products.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by Medicine Man Technologies, Inc. by a non affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com - +1(561)325-8757
SOURCE Financialnewsmedia.com
https://ml.globenewswire.com/media/d1ddb067-6e0a-4a92-b322-0f36ba8815a7/small/finacialnews-logo-final-01-2-png.png
A hint of things to come?
Mergers and acquisition’s article today mentioning Cvsi indirectly.
Here you go mike...
Factory in Kentucky to produce hempboard. Stronger than oak and grows in 6 months unlike oak which takes 60 years to mature.
Good for us. Bad for Big lumber.
https://www.facebook.com/629422471/posts/10157706390152472?sfns=mo
Yes. I certainly can’t remember all the stores we are in and which ones carry just topicals and which ones sell ingestibles.
Here n Texas it s just topicals af sprouts.
In my cliNic it’s everything. Gels, gummies, sprays, and mostly balms.
People love it.
I mix it with another product that sucks the whole compound into the body faster than just the balm alone.
I mentioned it to Stuart Tomc but he did not seem very terested in pursuing what I’m doing.
I also was asked to represent a pharma company that has a fantastic CBD sleep aid product. Reviews from patients are outstanding so far.
Ambien and that stuff should be on its way out soon.
Crow hunter...you are one of my favorite science fiction authors ever. I wish I had your imagination.
Hmmmmmmmm...
Are we in sprouts yet?
If not I guess we will be soon.
She is currently an Independent Board Director for Sprouts Farmers Market Inc., a $5 billion specialty retailer of natural and organic food focusing on health and wellness, where she serves as the Chairperson of the Nominating & Corporate Governance Committee and serves on the Compensation Committee.
When cvsi goes from otc to nasdaq here is what to expect...
What to Do When a Company Goes from the OTC to the Nasdaq
One company wants to play in the big leagues, and it could mean more money for investors…
With cannabis being illegal under U.S. federal law, most marijuana firms have to list on over-the-counter markets. Executives at the NYSE and Nasdaq are allowing Canadian companies to list on their exchanges because those companies operate a business that is legal under Canadian law.
But KushCo Holdings Inc. (OTC: KSHB), a California-based company, is trying to make an important move and get listed on the Nasdaq. KushCo doesn’t touch the plant. Instead, it provides packaging and consolation services to the industry. That’s one strategy to get in on the big action.
In the eyes of the Nasdaq, that should make it seem like less of a risk than approving a U.S. cannabis grower to list on its exchange.
Now, our members who own KushCo may wonder what they have to do when the shares go from over-the-counter to the Nasdaq.
The easy answer is nothing. You will still own the same amount of shares, and the shares will trade as normal.
You can just sit back.
However, in terms of what this means for the cannabis company itself, it’s significant.
Listing on the Nasdaq and NYSE can send share prices higher for a very specific reason…
Bigger Markets and More Money
Being on the NYSE or Nasdaq means more prestige, more eyeballs on your company, and more legitimacy.
When a stock gets uplisted, there’s a list of likely institutions that wanted to buy the stock before, but were unable or willing to buy it from a lower-level exchange. OTC stocks don’t have the liquidity people, like hedge fund executives, want to see.
Mutual funds and pension funds also avoid lower-level exchanges for the same reason.
By that, I mean it’s harder for a hedge fund to place an order for millions of shares at a price it wants, and it’s even harder to get out of a position because there just aren’t enough buyers. Fortunately for us, we don’t have that problem when buying OTC stocks because we have smaller trades that can get filled.
So, thanks to being on a bigger exchange, a company can start attracting more big-time investors. I know I keep harking on this, but I want all of our members to understand how everything will shake out.
A stock price without big institutional investors can be volatile.
That’s why you’re not going to see shares for Procter & Gamble Co. have wild 20% price swings in a single day.
You’ll never guess what our experts uncovered about this popular cannabis company. For all the details on this company -and over 170 more – just click here.
The Vanguard Group, an investment management firm with $5.3 trillion in assets under management as of September 2018, owns 214 million shares of Procter & Gamble.
And that’s what I mean about prices being stable. With so many shares, you know Vanguard isn’t going to make any rash decisions. Even if retail investors panic for some reason and try to sell their shares of P&G, it won’t match up to the amount of Procter & Gamble stock the Vanguard Group holds.
We’re getting to that point of institutional investments creating stability. We’ve even seen the Church of England dip its toes into medical marijuana investments.
The dominoes are falling, and the shining moment will be when institutions like the California Public Employees’ Retirement System, the State of Wisconsin Investment Board, and Goldman Sachs Asset Management start putting billions into cannabis stocks.
Think about how much more the shares you own today will be worth when these big institutions want to own what you already have.
Greg Miller
Executive Director, National Institute for Cannabis Investors
P.S. Thanks to one landmark announcement, the CBD market has exploded – virtually overnight. And with applications for chronic pain, seizures, insomnia, anxiety, and more experts predict the market to grow more than 15 times faster than the cannabis industry. They’re even predicting profits to jump 3,622% by 2022. With this kind of growth, investors would be crazy not to consider this market. That’s why our experts have identified two CBD companies with massive profit potential…. And you can find all the details right here.
Related Stocks: OTC: KushCo Holdings, Inc.
Certainly not a highly encouraging message from the FDA regarding any eminent movement of our stock. I’m convinced that the lack of up list to NASDAQ is due to FDA’s inability to rule on CBD. Too many unknowns. Then again that is what could lead to massive profits. We have a great company with great fundamentals which in the end of the day should allow us to be successful in our investment. Well the FDA recognizes the great demand and potential for CBD products it’s very confusing because they’re saying it is not legal even as a supplement. Well isn’t that what Cvsi is selling? Supplement. It’s certainly not a food additive as they are not selling protein drinks or candy bars with CBD in it
Fortunately Cvsi is not making any claims so they can not classify it as a drug. The widespread use of CBD and word-of-mouth is what is producing the claims. So what is your take on CBD as a supplement? Is it illegal?
Thanks for that video. I watch the whole thing. Excellent. I forwarded it on to several dozen doctor friends and personal friends.
Shares in an Ira cannot be shorted. However you should tell your broker do not allow my shares to be shorted if it’s not in an IRA
Good read for all longs. Thanks.
Large volume on no bad news. Sounds like a left attack.
Shooters gotta buy it back.
I bought also at 3.44.
Feels like shades of Andrew left
I was also told that plus CBD was the best seller at one of the chiropractic supply warehouses,
that is a big big supplier
This week I received a small brochure from the largest chiropractic and massage products supplier in the country. The name of the company is scrip hessco out of Illinois. When I called in to order some headrest paper I also inquired about the page full of five different CBD companies including Plus CBD.The salesman told me most of their CBD sales are for pain and the most prominent company was plus CBD.
He also told me that they are getting many many requests for CBD products.
On another note… The FDA and CDC are totally corrupt.
If the FDA pull some shenanigans with CBD it would not surprise me. there’s unconscionable decisions that both the FDA and CDC have reached regarding vaccinations and especially forest mandatory vaccinations. California New York West Virginia and Mississippi have already fallen to mandatory vaccines. If you want to send your kid to school even if he’s had a vaccine reaction , he/she still has to be up to date. Corruption is everywhere.
Here is a little anecdotal post.
One of my patients a 27-year-old female had much better success with her anxiety using the 25 mg softgels in the red as opposed to two of the 15 mg softgels in the gold. Obviously not a very large sample but we are learning how this stuff works.
Space lady.
My entry for 2nd qt is 16,595,000
Here is the condensed version of what the hemp roundtable said to the FDA.
Yesterday, the U.S. Hemp Roundtable provided formal written comments to the Food and Drug Administration, as part of the FDA’s efforts to develop a regulatory path for the sale of hemp-derived CBD. On May 31, the Roundtable testified at the FDA’s first public hearing that CBD was safe and that the agency should move expeditiously to promulgate regulations for the retail sale of hemp CBD products. On June 20, Roundtable leadership met privately with a dozen senior FDA officials that comprise the agency’s CBD Working Group to provide further analysis. Yesterday, the Roundtable shared a 29-page report with extensive safety data to back its recommendations.
Dozens of Roundtable member companies and organizations – including substantial assistance by its grassroots partner, the Hemp Industries Association – provided information for the Roundtable’s commentary. Of particular note is data about “adverse events” – company consumer reports about problems associated with CBD products:
As shown in the attached materials, one of our member companies sold approximately 580,000 products with zero serious adverse events reported to the company, and about 300 non-serious adverse reported for humans and animals. Another member company has sold over 1.4 million products, with zero serious adverse events and 623 non-serious adverse events. This company has also provided a thorough breakdown of its reported adverse events in the attached materials. A third member company provided a summary of adverse events/complaints related to human ingestion or topical application of their products along with the percentage of adverse events/complaints per units sold. A fourth company provided adverse events related to human ingestion and topical products reporting approximately 200 adverse events and zero serious adverse events, with over 2 million products sold. Notably, the percentage of AERs for these companies (serious and non-serious) is 0.01-0.1 percent.
Based on the data shared by Roundtable members, as well as significant research and public information, the Roundtable’s counsel concludes: “We believe that there are no unique safety concerns associated with the consumption of CBD that would preclude the use of FDA’s current regulatory framework in establishing product-specific acceptable levels of use.”
Ultimately, the Roundtable shared the following recommendations:
CBD does not appear to pose unreasonable safety risks to consumers and therefore can be regulated by FDA like any other botanical ingredient used in these products. This position is supported by clinical studies conducted at dosages at or above what is commonly used in dietary supplements, food, and cosmetics. Several of these studies are in sensitive populations.
Appropriate levels of CBD will be much lower in food and dietary ingredients than those used in pharmaceutical products. However, we advise against establishing arbitrary dose limits for these products as the effects of the CBD will vary greatly based on the intended use, formulation, and mode of delivery. Each manufacturer has the burden to establish its specific product formulation is safe for the intended population through FDA’s current regulatory framework.
Safety concerns that may arise from the lack of data in vulnerable populations such as children, pregnant or lactating women, and patients taking therapeutic levels of CBD can be addressed in the labeling of the product with adequate advisory language and directions for use.
FDA’s current regulatory system supports incentives for drug development, and clearly and sufficiently distinguishes these products from food and dietary ingredients based on their intended use and labeling.
The Roundtable urges FDA to use its existing authority under the FD&C Act to enforce the mandatory cGMPs to protect consumers from unsafe products and ensure that all hemp-derived products are produced in a quality, consistent manner and accurately labeled.
We also encourage FDA to consider adopting the standards provided in the U.S. Hemp Authority Guidance and work with standard-setting organizations such as ASTM, ANSI, AOAC, and USP to develop validated analytical testing and consensus-based standards for quality and safety. In future guidance or rulemaking, we also recommend that FDA to include consensus-based, validated standards and methods for cannabinoid content, specifically CBD and THC.
If FDA determines that standardized definitions are necessary, we encourage FDA to work with industry stakeholders to develop these definitions.
FDA should continue to actively enforce the adulteration and misbranding provisions of the FD&C Act to ensure consumers are informed of any risks associated with the use of hemp products.
Existing federal laws and regulations provide the most appropriate mechanism to inform consumers in a uniform, consistent manner of the potential risks of products that contain hemp-derived ingredients, thereby obviating the need for state restrictions.
FDA, rather than states, is best suited to determine whether the current labeling of dietary supplements and food containing hemp-derived ingredients should include additional language to inform consumers, in particular vulnerable sub-populations.
Should FDA determine that advisory language is necessary for products containing CBD or other hemp-derived ingredients, we recommend that FDA consider utilizing the advisory language provided in the U.S. Hemp Authority Guidance.
The Roundtable’s comments were one of several thousand submissions made before the FDA’s July 16 deadline. The agency has announced that it will report on its progress in late summer or early fall. We look forward to continued collaboration with the agency as it develops its final regulations.
I am a little disappointed in management. I sent Stewart upon his request a CV, curriculum vitae. They are over 50,000 chiropractors in the US. We deal predominately with pain. A popular brand besides charlottes web is CBD clinic. They advertise in our journals and of course are carried by some of the wholesale warehouses. I would like CVS I to have a booth at the state chiropractic conventions .
Perhaps they’re already doing it and maybe that’s why I have had no reply.
Interestingly at one of the wholesale warehouses I asked what is your top selling CBD product. It was the most expensive of the CBD Clinic product which has 250 mg of CBD. The bottom line I think is that when pain is the issue money is not a barrier. Even in my office I give the person a choice “do you want the regular or do you want the extra strength.?” They usually say extra strength. Personally I think the regular works just as well.
It has been a rough year so far but of course everybody’s waiting for the NASDAQ uplist which should add several dollars immediately to the share price.
Y’all should be happy to know that I make my contribution. I just placed an order yesterday for $1200 worth of product. I have had people thank me so much for relieving their pain using chiropractic and the CBD balm that they do 5 times a day at home. I have people calling me a magician. Now I’d like to work my magic on the share price.
Tick-tock tick-tock
This company has amazing fundamentals. Fortunately for us it is way underpriced.
Those two knuckleheads can’t shake my shares loose.
They just float some crap on the board and pray someone will respond to them so they can make their 7 bucks.
Sad and pathetic.
If we were denied nasdaq listing we would know it by now.
Uplist coming. When? Who knows but it’s coming.
Tic toc.
Hmmmmm...best reply ever on any board. You had me laughing out loud.
Montana jack is back is correct. The numbers don’t lie. However the reason for the numbers is what we all want to know. The other numbers also do not lie. Great financials. 4500 stores. Over 1000 health professional accounts. Large market share. Not to mention GRAS certified. These too are the numbers that matter and that’s why we longs are convinced we have a future winner.Not to mention that a year ago the stock was trading for under a dollar. Some of us who’ve been in a while have made big returns so we are patient. As warren buffet said” buy when there is fear, sell when there’s greed.”
Because the company must notify us within three days if our NASDAQ application is rejected we are quite convinced that has not been rejected. The question on everybody’s mind is when will we get up listed. Right before that time is the time to buy Big. !!!!!
There is so many indicators that the CBD market is big and getting bigger every single day.
For example today a patient came in and told me a man she knows here in town opened up a CBD store some while back. He now has five stores. And he started with not much money.
The dollars flowing into CBD cannot be denied. The forces pushing this forward also cannot be denied. Big time players in the government want it. Therefore it’s going to happen the question is how long. We know the FDA is having another discussion on July 16. Congress is pushing them along. Some states are making their own rules about CBD and beverages and in candy bars. It’s happening. These are the reasons why almost a cult like following has developed around CVSI.
But I must admit. The current price of the stock has me eating a lot of gummy‘s. But that’s good.
Have a great Fourth of July.
lol!
Great post!
You need to speak up. Say what’s on your mind.. Don’t hold back. Let it go.
Nothing new there.Big Pharma owns this country. How do you think all these mandatory vaccine laws have been pushed through. Money.
Julie Geberding, former head of fda now has big position at Merck.
Fantastic news. How many states is CBD from hemp legal in food and beverages? Illinois just became #11 for recreational mj.
FDA better act soon or Congress will. Years ahead of waiting is not acceptable to many states. Too much money involved.
CBD found effective against strep and staph infections.
Amazing qualities. No wonder big pharma wanted it hidden away.
https://www.id-hub.com/2019/06/23/asm-microbe-cannnabidiol-found-to-be-active-against-gram-positive-bacteria/